Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor.
about
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathwayCombination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a reviewEarly onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysisDecreased left perisylvian GABA concentration in children with autism and unaffected siblingsMagnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literatureNeuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466The GABAergic deficit hypothesis of major depressive disorder.Update on research and treatment of premenstrual dysphoric disorder.Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.Associations between prefrontal γ-aminobutyric acid concentration and the tryptophan hydroxylase isoform 2 gene, a panic disorder risk allele in women.GABA levels are decreased after stroke and GABA changes during rehabilitation correlate with motor improvement.Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers.Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression.Hippocampal adult neurogenesis is enhanced by chronic eszopiclone treatment in rats.Evidence for linkage and association of GABRB3 and GABRA5 to panic disorder.GABA-based evaluation of neurologic conditions: MR spectroscopy.Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.Antidepressant-like properties of α2-containing GABA(A) receptors.Evidence for inhibitory deficits in the prefrontal cortex in schizophrenia.GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studiesProton magnetic resonance spectroscopy in depressionThe brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study.Developmental changes in gamma-aminobutyric acid levels in attention-deficit/hyperactivity disorderPersonality Traits of Suicidality Are Associated with Premenstrual Syndrome and Premenstrual Dysphoric Disorder in a Suicidal Women Sample.Effect of rolipram, a phosphodiesterase enzyme type-4 inhibitor, on γ-amino butyric acid content of the frontal cortex in mice exposed to chronic mild stress.In vivo magnetic resonance spectroscopy of GABA: a methodological review.γ-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers.Differences between unipolar and bipolar I depression in the quantitative analysis of glutamic acid decarboxylase-immunoreactive neuropil.Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.GABAergic control of depression-related brain statesAnxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acidDetermining the in vivo transverse relaxation time of GABA in the human brain at 7T.Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy.GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression.Enhanced visual motion perception in major depressive disorder.Discovering imaging endophenotypes for major depression.The effectiveness of yoga for depression: a critical literature review.Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents.
P2860
Q21559605-D6C7F5FD-8E38-4473-A465-2049812A32F8Q24647208-7A9FC737-3419-4381-8BF2-6CD52807D204Q24647799-3A8BBA04-F889-4512-ACE1-A35F78135193Q27013590-DE2141B3-3228-42D4-A0B4-D99EF14D92C5Q27026039-B9656B75-A689-4BDE-8B33-37BD463C942CQ28236198-0A26DFE7-F21B-4E7F-913E-A0AE5A5118A5Q30464954-B3682CD1-8AE3-4D4B-B851-A1918A9186D7Q30475462-18A7BD03-7543-4ECF-A057-CFCBF70C7C06Q30906677-C7C7E5DF-EB24-43BF-89CC-BF81B09324ADQ30987882-F0116ED7-CCA1-4D51-96F6-8C49EAE26B44Q33630777-0C0AD1ED-12B3-40AB-8684-44ABC3986AA9Q33698708-889F0AF7-4617-422F-8CD0-D894EE24FD4BQ33738620-635B17A0-D06E-4839-97DB-61799B6B3ABAQ33802572-12BAFECA-9A79-41D1-B40B-BB5C68C52D8AQ34061181-6D99EB50-940F-43A5-9319-14AA074FD412Q34068930-1513243D-217A-400E-9AF0-FD380CF9E6FFQ34135715-471A6DC1-BA02-40C3-A456-73D32DC23316Q34181837-347A77F4-BD45-49A3-8BC2-1F4E004563B4Q34504773-1EEC0DD0-05E8-40CB-94AE-5BFDB2078F98Q35014889-263770AB-18A3-44B7-9C9D-7C93A16B8293Q35121218-A36BF916-3EE0-4CA2-9708-788DC0473EDBQ35702054-3A38AD13-BD19-4787-A897-A616EA07208CQ35811094-7E80EBE5-4127-4CA4-A8A7-62C4722DF773Q35813155-3D5B5395-1BCE-4624-AFF9-D4F372FCA9E7Q35919515-BB84976C-17AF-4B19-9AF1-BC89D2946E27Q35975217-50949E6B-A4C6-46AC-83B8-594D86CC10DBQ36060201-7DB70922-8FBA-4325-9225-5991F6BED06FQ36295861-8446B025-06C6-498E-9233-8CDB1A628E71Q36377434-480C650D-E193-40A5-A697-31A5E5369A48Q36387711-03E3E386-B577-41F1-B389-5D9AC046F4C2Q36593835-2CBCA8A9-23D9-4B23-A606-10E87D787A8BQ36668325-5A9BFDD4-BE54-411A-AA8F-9F5444C34012Q36701832-BDDBD739-6082-45B6-B95B-D64E1D7CA65FQ36724440-0A17C942-14F5-479A-98AD-F7A9F828E29FQ37139874-B6C16E31-BEC1-4C7D-BB82-39A9A9D47C42Q37408446-21C9957F-3F8D-4048-8EC5-3BE93CC2D225Q37410419-3D87C202-C309-4FBD-A5A3-3294EFD63EE9Q37878247-0B57C942-DD9A-4073-8247-C80852D145B3Q38202162-4D8FC94C-F55D-4E64-A75B-E294E7D15314Q38310492-B163B43F-4A68-4007-A9BA-B9F1D7F0041D
P2860
Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@ast
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@en
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@nl
type
label
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@ast
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@en
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@nl
prefLabel
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@ast
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@en
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@nl
P50
P1476
Increased brain GABA concentra ...... serotonin reuptake inhibitor.
@en
P2093
Marzena Wylezinska
Zubin Bhagwagar
P304
P356
10.1176/APPI.AJP.161.2.368
P407
P577
2004-02-01T00:00:00Z